Epithelioid myxofibrosarcoma developing at the injection site of Adalimumab therapy for psoriatic synovitis

Area of Science:

• Oncology
• Immunology
• Dermatology

Background:

• The link between inflammation and cancer is a key research area.
• Biologic therapies, including Tumor Necrosis Factor (TNF) inhibitors, are used for autoimmune diseases.
• While overall cancer risk isn't elevated, anti-TNF therapies are linked to increased cutaneous malignancy and melanoma in some patients.

Purpose of the Study:

• To report the first instance of a soft tissue sarcoma at an Adalimumab injection site.
• To review existing literature on malignancies associated with anti-TNF therapies.
• To advocate for improved adverse event documentation for biologic therapies.

Main Methods:

• Case presentation of a patient with psoriatic synovitis treated with Adalimumab.
• Literature review of adverse events, specifically malignancies, associated with anti-TNF therapies.
• Analysis of potential iatrogenic risks.

Main Results:

• A sarcoma of the dermis and superficial subcutaneous tissue developed at the Adalimumab injection site.
• Existing literature indicates an increased risk of cutaneous malignancy and melanoma with anti-TNF use.
• This case represents a rare soft tissue sarcoma linked to Adalimumab therapy.

Conclusions:

• A rare soft tissue sarcoma occurred at the Adalimumab injection site in a patient with psoriatic synovitis.
• Enhanced adverse event reporting is crucial for understanding rare cancer risks associated with biologic therapies.
• Further investigation is needed to clarify the iatrogenic risk of soft tissue sarcomas in patients using anti-TNF agents.